 Buprenorphine
"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 2 | 1 | 3 | | 2018 | 2 | 2 | 4 | | 2019 | 6 | 5 | 11 | | 2020 | 15 | 1 | 16 | | 2021 | 13 | 0 | 13 | | 2022 | 16 | 0 | 16 | | 2023 | 21 | 0 | 21 | | 2024 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Christine PJ, Chahine RA, Kimmel SD, Mack N, Douglas C, Stopka TJ, Calver K, Fanucchi LC, Slavova S, Lofwall M, Feaster DJ, Lyons M, Ezell J, Larochelle MR. Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements. JAMA Netw Open. 2024 Aug 01; 7(8):e2425999.
-
Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 07; 119(7):1313-1321.
-
Shahlapour M, Singh S, Christine PJ, Laks J, Evans J, Farrell NM, Khan GK, Taylor JL, Rozansky H. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic. J Addict Med. 2024 May-Jun 01; 18(3):345-347.
-
Callister C, Porter S, Vatterott P, Keniston A, McBeth L, Mann S, Calcaterra SL, Limes J. The Impact of Completing X-Waiver Training and Clinical Addiction Exposure on Internal Medicine Residents Treating Patients With Opioid Use Disorder. Subst Use Addctn J. 2024 Jul; 45(3):356-366.
-
Fine DR, Critchley N, Hart K, Joyce A, Sporn N, Gaeta J, Wright J, Baggett TP, Kruse G. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program. Subst Use Addctn J. 2024 Apr; 45(2):268-277.
-
Gibbons JB, McCullough JS, Zivin K, Brown ZY, Norton EC. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare. J Subst Use Addict Treat. 2024 02; 157:209271.
-
Stern SJ, D'Orazio JL, Work BD, Calcaterra SL, Thakrar AP. Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal? J Hosp Med. 2024 Apr; 19(4):339-343.
-
Christine PJ, Larochelle MR, Lin LA, McBride J, Tipirneni R. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder. JAMA Health Forum. 2023 Oct 06; 4(10):e233549.
-
Fernald DH, Nease DE, Westfall JM, Kwan BM, Dickinson LM, Sofie B, Lutgen C, Carroll JK, Wolff D, Heeren L, Felzien M, Zittleman L. A randomized, parallel group, pragmatic comparative-effectiveness trial comparing medication-assisted treatment induction methods in primary care practices: The HOMER study protocol. PLoS One. 2023; 18(9):e0290388.
-
Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 09 05; 6(9):e2329583.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|